Vanda Pharmaceuticals has filed a patent for a method of administering tasimelteon, a drug used to treat circadian rhythm and sleep disorders. The method involves orally administering an effective dose of tasimelteon under fasted conditions, without food. The patent also includes a claim for a packaged pharmaceutical composition that includes tasimelteon capsules and printed instructions to take the drug without food. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a method of administering tasimelteon without food
A recently filed patent (Publication Number: US20230293477A1) describes a packaged pharmaceutical composition that includes tasimelteon capsules and printed information. The capsules contain a dose of 20 mg of tasimelteon, a pharmaceutical compound used for certain medical conditions. The printed information provides an important instruction that tasimelteon should be taken without food.
The printed information in the packaging includes specific instructions regarding the timing of taking tasimelteon in relation to food consumption. The instructions state that tasimelteon should be taken with no food for a certain period of time prior to administration. The options provided range from at least one-half hour to three hours prior to taking the medication.
Additionally, the patent mentions that the packaged pharmaceutical composition may also include a container to hold the tasimelteon capsules.
This patent application highlights the importance of taking tasimelteon without food. The specific instructions provided in the packaging aim to ensure the optimal effectiveness and absorption of the medication. By specifying the time period during which tasimelteon should be taken without food, the patent seeks to provide clear guidance to patients and healthcare professionals.
The inclusion of a container within the packaged pharmaceutical composition adds convenience and organization to the product. This container holds the tasimelteon capsules, keeping them secure and easily accessible.
Overall, this patent application introduces a packaged pharmaceutical composition that includes tasimelteon capsules and printed information with specific instructions regarding food consumption. The patent aims to provide a clear and convenient solution for administering tasimelteon, ensuring its optimal effectiveness for patients.
To know more about GlobalData’s detailed insights on Vanda Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
